Aclarion, Inc. (Nasdaq: ACON, ACONW) has published a shareholder letter from Chief Executive Officer Brent Ness, outlining strategic progress and key catalysts for 2026. The company, which leverages biomarkers and augmented intelligence to help physicians identify the source of chronic low back pain, is pursuing reimbursement coverage from one or more regional insurance providers in the United States as a step toward broader payer adoption. The letter also highlights the upcoming initial readout of the CLARITY clinical trial in the fourth quarter of 2026 and notes that the company maintains a strong balance sheet with cash runway into 2028.
According to the letter, Aclarion is focusing on disciplined execution against catalysts that can expand adoption of its Nociscan platform. The company has been advancing reimbursement initiatives both in the United Kingdom and the United States, alongside growing clinical evidence and commercial engagement with physicians and imaging centers. "With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders," Ness stated.
The Nociscan platform uses magnetic resonance spectroscopy data from an MRI machine to extract and quantify chemical biomarkers associated with disc pain. Proprietary algorithms then indicate whether a disc may be a source of pain, providing physicians with critical insights to optimize treatment strategies. The letter is available on the company's website.
Aclarion's focus on reimbursement is a critical step toward making Nociscan more accessible to patients and providers. The company's strong cash position, with runway into 2028, provides financial stability to execute its strategic plan. The CLARITY trial's initial data readout, expected in late 2026, could provide further evidence supporting the platform's clinical utility.
Forward-looking statements in the press release include expectations regarding patient enrollment in the ongoing clinical trial, an initial interim data readout later in 2026, and the potential benefits of Nociscan technology. These statements are subject to risks and uncertainties detailed in the company's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2025.
